title: Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008).
abstract: BACKGROUND
  Adalimumab is a second generation humanized anti-tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn's disease (CD).
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of adalimumab on a nationwide clinical setting.
  
  
  METHODS
  We used the Scottish Society of Gastroenterology network to identify and follow up the clinical outcomes of patients with CD treated with adalimumab over a 4-year period (2004-2008).
  
  
  RESULTS
  A total of 98 patients received adalimumab - 100.5 patient follow-up years were recorded (64.3% females; median age at diagnosis of 20.7 years; 88.8% treated with 80/40 mg induction regimen. Eighty eight (89.8%) had previous infliximab with 29 (32.9%) primary nonresponders; 32 (32.6%) were corticosteroid-dependent; 47 (47.9%) were intolerant/resistant to most immunosuppressive therapies (two or more). In all, 60% of patients were in clinical remission at 1-year follow-up, with 30% and 55% requiring dose escalation to weekly therapy at 1-and 2-year follow-up respectively. Overall, 29 (29.6%) patients developed complications with eight nonfatal serious (8.2%) adverse events and 2 (2.0%) case fatalities (sepsis following perforation and disseminated colorectal cancer, respectively).
  
  
  CONCLUSIONS
  Adalimumab is efficacious in severe and refractory CD in the clinical setting, although there remain significant therapy- and disease-related risks of serious complications.
authors.affiliation: Scottish Society of Gastroenterology, Edinburgh, UK. gwotzerho@aol.co.uk
authors.forename: G T
authors.initials: GT
authors.lastname: Ho
authors.forename: A
authors.initials: A
authors.lastname: Mowat
authors.forename: L
authors.initials: L
authors.lastname: Potts
authors.forename: A
authors.initials: A
authors.lastname: Cahill
authors.forename: C
authors.initials: C
authors.lastname: Mowat
authors.forename: C W
authors.initials: CW
authors.lastname: Lees
authors.forename: N C
authors.initials: NC
authors.lastname: Hare
authors.forename: J A
authors.initials: JA
authors.lastname: Wilson
authors.forename: R
authors.initials: R
authors.lastname: Boulton-Jones
authors.forename: M
authors.initials: M
authors.lastname: Priest
authors.forename: D A
authors.initials: DA
authors.lastname: Watts
authors.forename: A G
authors.initials: AG
authors.lastname: Shand
authors.forename: I D
authors.initials: ID
authors.lastname: Arnott
authors.forename: R K
authors.initials: RK
authors.lastname: Russell
authors.forename: D C
authors.initials: DC
authors.lastname: Wilson
authors.forename: A J
authors.initials: AJ
authors.lastname: Morris
authors.forename: J
authors.initials: J
authors.lastname: Satsangi
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D012606:Scotland; D013223:Statistics as Topic; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab